SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Moreover,sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1(GLP1) receptor agonists are reported to lower the serum liver enzymes, liverfibrosis index, and liver fat and should be considered for patients with type 2diabetes and NAFLD [89, 90].